克罗恩病内镜下疾病活动度指数的反应性评估
该研究利用阿达木单抗治疗试验中112对结肠镜视频,评估简化内镜评分(SES-CD)和克罗恩病内镜严重度指数(CDEIS)对疾病活动度变化的反应性。结果显示两种指数均与整体内镜评估高度相关,SES-CD在两种变化定义下效应量均数值上高于CDEIS,但两种指数对变化仅中度敏感。
要点
- SES-CD与CDEIS均与整体内镜严重度评估高度相关,均为有效的内镜活动度指标。
- 基于治疗分组的标准化效应量:SES-CD为0.84,CDEIS为0.72。
- 基于PRO2绝对变化≥50分的标准化效应量:SES-CD为0.76,CDEIS为0.70。
核心结论
- SES-CD和CDEIS均是有效的内镜疾病活动度测量工具,对内镜活动度变化具有中度反应性。
- 在本数据集中,SES-CD显示出数值上更高的反应性。
研究设计与样本
- 研究利用阿达木单抗治疗试验中克罗恩病患者的112对结肠镜视频记录(基线及第8-12周),由四名中心阅片者随机顺序、双份独立审阅(2组阅片者共审阅56对视频)。
- 通过比较SES-CD和CDEIS变化评分与整体内镜严重度评估(GELS)、患者报告结局(PRO2)及克罗恩病活动指数(CDAI)的相关性,并计算标准化效应量和Guyatt反应性统计量(GRS)来评估反应性,变化定义包括治疗分组和PRO2总分绝对变化≥50分。
主要发现
- 两种内镜工具与GELS的变化高度相关。
- 基于治疗分组,SES-CD的标准化效应量为0.84(95%CI 0.53-1.15),GRS为0.79(95%CI 0.48-1.09);CDEIS的标准化效应量为0.72(95%CI 0.42-1.02),GRS为0.75(95%CI 0.45-1.06)。
- 基于PRO2总分绝对变化≥50分,SES-CD的标准化效应量为0.76(95%CI 0.49-1.02),GRS为0.93(95%CI 0.64-1.21);CDEIS的标准化效应量为0.70(95%CI 0.44-0.97),GRS为0.83(95%CI 0.55-1.10)。
- 移除狭窄作为索引项目及调整观察肠段数量未改善反应性估计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Crohn's Disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for Crohn's Disease (SES-CD) are commonly used to assess Crohn's disease (CD) activity; however neither instrument is fully validated. We evaluated the responsiveness to change of the SES-CD and CDEIS using data from a trial of adalimumab, a drug therapy of known efficacy. METHODS: Paired video recordings (N=112) of colonoscopies (baseline and week 8-12) obtained from patients with CD who participated in a trial of adalimumab therapy were reviewed in random order, in duplicate, by four central readers (56 pairs of videos by 2 groups of readers). Responsiveness of the SES-CD and the CDEIS was evaluated by comparing correlations between the observed and pre-specified predictions of change scores for these endoscopic indices with a global endoscopic evaluation of severity (GELS), a patient reported outcome (PRO2), and the Crohn's disease activity index (CDAI), and by calculation of the standardized effect size, and Guyatt's Responsiveness statistic (GRS) using 2 definitions of change; (1) treatment assignment and (2) an absolute change in total PRO2 of 50. The potential application of effect size estimates was demonstrated by calculating hypothetical sample sizes for comparing two independent groups. The impact of removing stenosis as an index item and adjusting for the number of segments observed was also assessed. RESULTS: Changes in both endoscopic instruments and the GELS were highly correlated. The SES-CD displayed numerically higher effect sizes for both definitions of change. The standardized effect size and GRS estimates (95% confidence interval) for the SES-CD based on treatment assignment were 0.84 (0.53, 1.15) and 0.79 (0.48, 1.09). Corresponding values for the CDEIS were 0.72 (0.42, 1.02) and 0.75 (0.45, 1.06). The standardized effect size and GRS estimates for the SES-CD based on an absolute change in total PRO2 of 50 points or greater were 0.76 (0.49, 1.02) and 0.93 (0.64, 1.21). Corresponding values for CDEIS were 0.70 (0.44, 0.97), 0.83 (0.55, 1.10). Removal of stenosis as an index item and adjusting for observed segments did not improve responsiveness estimates. CONCLUSIONS: Although both the SES-CD and CDEIS are valid measures of endoscopic disease activity that are moderately responsive to changes in endoscopic disease activity, the SES-CD displayed numerically greater responsiveness in this data set.
引用
- Khanna R, Zou G, Stitt L, et al. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017. PMID: 28071654. doi:10.1038/ajg.2016.580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。